Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.

Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein: i) the nanoparticles and/or nanoparticles of said aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticles and nanoparticle aggregates being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising the nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using an X-ray imaging equipment.

Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring, typically in the context of therapy, in particular in the context of oncology, to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticle aggregates, wherein: i) the density of each nanoparticle and of each nanoparticle aggregate is at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C.

Abstract: The present application relates to activatable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Abstract: The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.

Abstract: The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.

Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient's monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein i) the nanoparticle and/or nanoparticles of the aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using X-ray imaging equipment.

Abstract: The present invention relates to compositions and methods for use in medical diagnostic and patient monitoring, typically in the context of therapy, in particular in the context of oncology to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticles aggregates, wherein i) the density of each nanoparticle and of each nanoparticle aggregate is of at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising nanoparticles and/or nanoparticle aggregates, is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C.

Abstract: The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.